T0	Participants 45 85	children with autism spectrum disorders:
T1	Participants 242 303	children with autism spectrum disorders (ASD) ages 3-8 years.
T2	Participants 312 390	Phase 1 involved 65 children with ASD who received one round of DMSA (3 days).
T3	Participants 391 491	Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2.
T4	Participants 495 628	phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.
T5	Participants 1323 1388	children with ASD who have high urinary excretion of toxic metals